If You Invested in Adaptimmune Therapeutics Plc (ADAPY)

Adaptimmune Therapeutics plc (ADAPY) is a biopharmaceutical company focused on cell therapies for the treatment of solid tumor cancers. According to company disclosures, Adaptimmune works to redefine how solid tumors are treated by developing engineered T-cell therapies designed to target cancer cells.

The company’s American Depositary Shares (ADSs) were voluntarily delisted from Nasdaq, and the ADSs are quoted on the OTC Pink Limited Market under the symbol ADAPY. Adaptimmune has also initiated a process for deregistration of its ADSs under Section 12(b) of the Securities Exchange Act of 1934, including the filing of a Form 25 and a Form 15 with the U.S. Securities and Exchange Commission. Following the Form 15 filing, the company’s periodic reporting obligations under the Exchange Act were suspended.

Business focus and therapeutic approach

Adaptimmune describes itself as a biopharmaceutical company working with cell therapies for solid tumor cancers. Its work centers on engineered T-cell therapies, which are designed to recognize and attack cancer cells. The company’s activities include the development of clinical and pre-clinical candidates that target specific antigens associated with certain cancers.

The company reports that the U.S. Food and Drug Administration (FDA) approved its first biologics license application (BLA) for TECELRA (afamitresgene autoleucel), described as the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the United States. This approval represents a key milestone in Adaptimmune’s efforts to bring engineered T-cell therapies to patients with solid tumors.

Key programs and assets

Adaptimmune has disclosed several key assets and programs related to its cell therapy platform:

• TECELRA (afamitresgene autoleucel): An engineered T-cell therapy that received FDA approval for the treatment of a solid tumor cancer in the United States. The company states that this therapy is the first engineered T-cell therapy approved in the U.S. for a solid tumor indication.
• Letetresgene autoleucel (lete-cel): A clinical program for people with synovial sarcoma and myxoid liposarcoma. According to the company, a commercial launch for lete-cel was planned in connection with a transaction involving this asset.
• Uza-cel: A third clinical candidate, which was part of a collaboration with Galapagos related to this cell therapy.
• PRAME-directed T-cell therapy: A pre-clinical asset targeting PRAME, which the company identifies as part of its remaining portfolio.
• CD70-directed TRuC therapy: Another pre-clinical asset, described as a CD70-directed TRuC therapy, for which the company is exploring strategic options.

Adaptimmune has indicated that it is seeking strategic options for its pre-clinical assets, including the PRAME-directed T-cell therapy and the CD70-directed TRuC therapy. This reflects a focus on maximizing value from its remaining programs following a significant transaction involving its clinical-stage assets.

Transaction with US WorldMeds

The company reports that USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, US WorldMeds), acquired TECELRA along with lete-cel and uza-cel. Adaptimmune states that this transaction allows TECELRA to continue to be made available to patients and that work has been ongoing to ensure a smooth transition of activities associated with TECELRA, lete-cel, and uza-cel to US WorldMeds.

Adaptimmune also notes that it continues to support US WorldMeds with a goal to achieve approval for lete-cel, with the hope that this therapy will benefit patients in the future. At the same time, the company emphasizes its intention to focus on extracting value from its remaining pre-clinical assets.

Corporate structure and governance changes

Adaptimmune has announced significant changes to its Board of Directors and executive leadership team in connection with a restructuring. The company reports that its Chief Financial Officer, Christopher (Chris) Hill, has been appointed Chief Executive Officer and a Director, while continuing to serve as CFO. Several prior board members and executives have left the company in connection with this restructuring.

Following these changes, the Board is described as comprising three members: Lawrence Alleva (Chairman), Garry Menzel, and Chris Hill (who also serves as CEO and CFO). These changes are presented by the company as part of its broader restructuring and cost-reduction efforts associated with delisting and deregistration.

Trading status and regulatory reporting

Adaptimmune’s ADSs are quoted on the OTC Pink Limited Market under the symbol ADAPY. The company has voluntarily delisted its ADSs from Nasdaq and has initiated deregistration under Section 12(b) of the Exchange Act. It has filed a Form 25 and a Form 15 with the SEC, and states that, upon filing of the Form 15, its obligations to file periodic reports under the Exchange Act were suspended.

The company has indicated that delisting from Nasdaq and deregistration are expected to reduce its costs as a public company. This is presented as part of its efforts to maximize value going forward, particularly in light of the transaction with US WorldMeds and its focus on remaining assets.

Strategic focus going forward

According to Adaptimmune, its current focus includes:

• Supporting US WorldMeds in the transition and further development of TECELRA, lete-cel, and uza-cel.
• Maintaining efforts to maximize value from its remaining pre-clinical assets, including PRAME-directed and CD70-directed TRuC therapies.
• Reducing public company costs through delisting and deregistration of its ADSs.

The company’s disclosures emphasize the importance of its transaction with US WorldMeds for continued patient access to TECELRA and the potential future impact of lete-cel and uza-cel, while also highlighting its intention to seek strategic options for its pre-clinical pipeline.

FAQs about Adaptimmune (ADAPY)